Blue Jet Healthcare Limited (BLUEJET)

Healthcare · Pharmaceuticals & Biotechnology · NSE · Updated 15 July 2026

₹598.55 ↓ 37.72% (1Y)

🎯 Key Takeaways

Blue Jet Healthcare is in a strategic reinvestment phase, transitioning from stable profitability to growth-oriented expansion despite near-term revenue headwinds. Management is prioritizing long-term positioning in contrast media and new product segments, supported by significant capex and a debt-free balance sheet, while navigating a challenging revenue environment.
⚠️ Near-term revenue decline in core PI/API segments may continue to pressure overall growth until contrast media and new products gain sufficient tracti

Market Cap

₹7,466

P/E Ratio

25.4

Div Yield

0.00%

Promoter

0.0%

✨ Ask AI About BLUEJET 📊 Interactive Charts

📖 The Story

Blue Jet Healthcare is in a strategic reinvestment phase, transitioning from stable profitability to growth-oriented expansion despite near-term revenue headwinds. Management is prioritizing long-term positioning in contrast media and new product segments, supported by significant capex and a debt-free balance sheet, while navigating a challenging revenue environment.

📰 What's Happening

In FY26, the company reported an 8% YoY revenue decline to ₹947 crores, driven by a 35% drop in PI/API revenue, though contrast media grew 23% to ₹495 crores. Despite flat EBITDA margin at 31%, management highlighted double-digit growth targets for FY27 fueled by new product launches and validated demand. A ₹400 crore capex plan for FY27 is underway, focused on expanding the Vizag facility, with ramp-up expected over 24-30 months. The company raised ₹8,000 million via qualified institutional placement in July 2026 to fund this expansion, approved by shareholders in a June 18 EGM. Management emphasized that the capital raise supports strategic growth without altering existing ownership structures.

Source: Stock Announcements

🔮 Management Outlook & What's Next

Management expressed confidence in achieving double-digit growth in FY27, underpinned by new product launches and expanding demand in contrast media. They highlighted the Vizag plant's phased ramp-up over the next 2-3 years as a key enabler for capacity and product diversification. Capex of ₹400 crores is being deployed in a structured manner across FY27 and beyond, with no specific ROI targets disclosed. Management did not provide quarterly guidance but emphasized that the fundraise and expansion are aligned with long-term structural growth ambitions rather than short-term earnings acceleration.

Extracted from official company announcements. Not StockFin.ai's opinion.

⚖️ Peer Comparison — Pharmaceuticals & Biotechnology

Company	MCap (₹ Cr)	P/E	ROCE	ROE	D/E
Sun Pharmaceutical Industries Limited	4.51 L Cr	41.3	20.3%	15.1%	0.03
Divi's Laboratories Limited	1.79 L Cr	72.4	22.1%	16.6%	0.00
Torrent Pharmaceuticals Limited	1.49 L Cr	80.1	—	—	—
Cipla Limited	1.16 L Cr	25.4	19.4%	14.6%	0.00
Dr. Reddy's Laboratories Limited	1.12 L Cr	20.0	19.7%	16.6%	0.12
Lupin Limited	1.04 L Cr	36.2	—	—	—
Mankind Pharma Limited	1.03 L Cr	49.2	—	—	—
Zydus Lifesciences Limited	1.02 L Cr	22.5	—	—	—
Aurobindo Pharma Limited	87,806	25.3	—	—	—
Laurus Labs Limited	71,455	356.8	—	—	—

🔗 Peer Stock Analyses

SUNPHARMA DIVISLAB TORNTPHARM CIPLA DRREDDY

⚠️ Risk Factors

1. Near-term revenue decline in core PI/API segments may continue to pressure overall growth until contrast media and new products gain sufficient traction. 2. Capex execution delays or cost overruns at the Vizag facility could impact timelines for revenue recovery. 3. Margin compression from logistics and crude oil cost inflation remains a near-term headwind with no immediate mitigation strategy disclosed. 4. Market sentiment remains weak, as reflected in the 1-year return of -37.72%, which may limit investor tolerance for execution risks.

📋 Recent Filings

🧠 Analyst's Read

Blue Jet Healthcare is executing a capital-intensive turnaround strategy focused on high-margin contrast media and new product segments, supported by strong liquidity and institutional backing. Investors should monitor the pace of Vizag ramp-up and the contribution of new launches to top-line growth in the next 2-3 quarters, as near-term margin pressures and flat revenue trends pose near-term challenges to sentiment.

Based on filing content and financial data. Not a recommendation.

Read the full analysis

Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.

2 free AI queries per day.

✨ Deep Dive with AI on BLUEJET

Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-07-15.

📡 Get AI alerts when BLUEJET files new disclosures

Track BLUEJET filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track BLUEJET — Free

Free account · 2 AI queries/day